What Natera, Inc. told the SEC could break it.

If FDA adopts an alternate LDT framework or Congress grants FDA LDT authority, Natera could be forced to stop selling tests or modify them while pursuing premarket authorization, adversely affecting the business.

“If FDA develops an alternate approach to regulating LDTs, or if Congress enacts legislation giving FDA authority to regulate our current or future LDTs, or any components or materials we use in, or software that we or our customers use as part of, our tests, we may be forced to stop selling our tests or we may be required to modify claims for or make other changes to our tests while we or our suppliers work to comply with FDA requirements including, potentially, premarket authorization.”

Revenue depends on reimbursement from commercial insurers and federal health programs via CPT coding; coverage and reimbursement determinations (and clinical-evidence-driven guideline changes) directly drive results.

“We receive reimbursement for our tests from third-party payers, which includes commercial health insurers and federal health care programs (as defined under 42 U.S.C. 1320a-7b(f)). Laboratory tests, as with most other health care services, are classified for reimbursement purposes under a coding system known as Current Procedure Terminology, or CPT, which we and our customers must use to bill and receive reimbursement for our diagnostic tests.”

Natera's labs (Austin, San Carlos, Boulder) must comply with CLIA; non-compliance can lead CMS to revoke certificates, impose penalties, and suspend or exclude the lab from Medicare/Medicaid.

“Our laboratories located in Austin, Texas; San Carlos, California; and Boulder, Colorado are CLIA certified, and must comply with all applicable CLIA regulations and standards. If a clinical laboratory is found to be out of compliance with CLIA standards, CMS may impose sanctions; suspend, limit or revoke the laboratory's CLIA certificate”

Core inputs are sole-sourced: Illumina is the only validated sequencer/reagent supplier (agreement to Aug 2033) and Streck is the exclusive blood-collection-tube supplier; loss of either would halt testing.

“In particular, our sequencers, many of our reagents, including for Panorama, Horizon and Signatera as described below, and our blood collection tubes, are sole sourced. For example, our molecular diagnostics tests are currently only validated to perform on Illumina's sequencing platform; in addition, Illumina is currently the sole supplier of our sequencers and related reagents for Panorama, Horizon, Signatera and Prospera, along with certain hardware and software, pursuant to a supply agreement that expires in August 2033.”